Cyclooxygenases: New forms, new inhibitors, and lessons from the clinic

FASEB Journal

Volumn 18, Issue 7, 2004, Pages 790-804

  Warner, Timothy D ^a   Mitchell, Jane A ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Celecoxib; Cyclooxygenase 2; Nonsteroidal anti inflammatory drugs; Rofecoxib; Thrombosis

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; ETORICOXIB; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LUMIRACOXIB; MECLOFENAMIC ACID; MEFENAMIC ACID; MELOXICAM; MOBICOX; NABUMETONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENYLBUTAZONE; PIROXICAM; ROFECOXIB; SULINDAC; TENOXICAM; TOLMETIN; UNINDEXED DRUG; VALDECOXIB;

ASTHMA; BRAIN TISSUE; CANCER GROWTH; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; COLON ADENOMA; DIARRHEA; DISEASE SEVERITY; DRUG RESEARCH; DRUG SCREENING; DRUG SELECTIVITY; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERTENSION; INTESTINE; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; KIDNEY PARENCHYMA; META ANALYSIS; NOCICEPTION; NONHUMAN; OSTEOARTHRITIS; PANCREAS; PRIORITY JOURNAL; PROTEIN FUNCTION; REPRODUCTION; REVIEW; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW; TABLET FORMULATION; THROMBOSIS;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTHMA; CARDIOVASCULAR DISEASES; COLONIC NEOPLASMS; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; DRUG ERUPTIONS; FEMALE; GASTRIC MUCOSA; HUMANS; INFLAMMATION; INTESTINAL MUCOSA; KIDNEY; MALE; MICE; PAIN THRESHOLD; PEPTIC ULCER; PREGNANCY; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; RATS; REPRODUCTION; WOUND HEALING;

EID: 2142695733     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.03-0645rev     Document Type: Review

References (159)

1. Wu, K. K. (1995) Inducible cyclooxygenase and nitric oxide synthase. Adv. Pharmacol. 33, 179-207
2. Seibert, K., Zhang, Y., Leahy, K., Hauser, S., Masferrer, J., and Isakson, P. (1997) Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv. Exp. Med. Biol. 400A, 167-170
3. Vane, J. R., Bakhle, Y. S., and Botting, R. M. (1998) Cyclooxygenase 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38, 97-120
4. Mitchell, J. A., and Warner, T. D. (1999) Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br. J. Pharmacol. 128, 1121-1132
5. Smith, W. L., DeWitt, D. L., and Garavito, R. M. (2000) Cyclooxygenases: structural, cellular and molecular biology. Annu. Rev. Biochem. 69, 145-182
6. DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., Van De Putte, L. B. A., and Lipsky, P. E. (1998) Cyclooxygenase in biology and disease. FASEB J. 12, 1063-1073
7. FitzGerald, G. A., and Patrono, C. (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345, 433-442
8. Marrache, A. M., Gobeil, F., Jr., Bernier, S. G., Stankova, J., Rola-Pleszczynski, M., Choufani, S., Bkaily, G., Bourdeau, A., Sirois, M. G., Vazquez-Tello, A., et al. (2002) Proinflammatory gene induction by platelet-activating factor mediated via its cognate nuclear receptor. J. Immunol. 169, 6474-6481
9. Subbaramaiah, K., Lin, D. T., Hart, J. C., and Dannenberg, A.J. (2001) Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J. Biol. Chem. 276, 12440-12448
10. Yang, W. L., and Frucht, H. (2001) Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 22, 1379-1383
11. Sheng, H., Shao, J., and Dubois, R. N. (2001) K-Ras mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1. Cancer Res. 61, 2670-2675
12. Sheng, H., Shao, J., Dixon, D. A., Williams, C. S., Prescott, S. M., DuBois, R. N., and Beauchamp, R. D. (2000) Transforming growth factor-b1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J. Biol. Chem. 275, 6628-6635
13. Chandrasekharan, N. V., Dai, H., Roos, K. L., Evanson, N. K., Tomsik, J., Elton, T. S., and Simmons, D. L. (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. USA 99, 13926-13931
14. Dinchuk, J. E., Liu, R. Q., and Trzaskos, J. M. (2003) COX-3: in the wrong frame in mind. Immunol. Lett. 86, 121
15. Kis, B., Snipes, J. A., Isse, T., Nagy, K., and Busija, D. W. (2003) Putative cyclooxygenase-3 expression in rat brain cells. J. Cereb. Blood Flow Metab. 23, 1287-1292
16. Simmons, D. L., Botting, R. M., Robertson, P. M., Madsen, M. L., and Vane, J. R. (1999) Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs. Proc. Natl. Acad. Sci. USA 96, 3275-3280
17. Schade, S., Bezugla, Y., Kolada, A., Kamionka, S., Scheibe, R., and Dieter, P. (2002) Diverse functional coupling of cyclooxygenase 1 and 2 with final prostanoid synthases in liver macrophages. Biochem. Pharmacol. 64, 1227-1232
18. 2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. J. Biol. Chem. 274, 3103-3115
19. Xu, S., and Venge, P. (2000) Lipocalins as biochemical markers of disease. Biochim. Biophys. Acta 1482, 298-307
20. Urade, Y., and Eguchi, N. (2002) Lipocalin-type and hematopoietic prostaglandin D synthases as a novel example of functional convergence. Prostaglandins Other Lipid Mediat. 68-69, 375-382
21. Watanabe, K. (2002) Prostaglandin F synthase. Prostaglandins Other Lipid Mediat. 68-69, 401-407
22. Winchester, S. K., Imamura, T., Gross, G. A., Muglia, L. M., Vogt, S. K., Wright, J., Watanabe, K., Tai, H. H., and Muglia, L. J. (2002) Coordinate regulation of prostaglandin metabolism for induction of parturition in mice. Endocrinology 143, 2593-2598
23. Hara, S., Miyata, A., Yokoyama, C., Inoue, H., Brugger, R., Lottspeich, F., Ullrich, V., and Tanabe, T. (1994) Isolation and molecular cloning of prostacyclin synthase from bovine endothelial cells. J. Biol. Chem. 269, 19897-19903
24. Korita, D., Sagawa, N., Itoh, H., Yura, S., Yoshida, M., Kakui, K., Takemura, M., Yokoyama, C., Tanabe, T., and Fujii, S. (2002) Cyclic mechanical stretch augments prostacyclin production in cultured human uterine myometrial cells from pregnant women: possible involvement of up-regulation of prostacyclin synthase expression. J. Clin. Endocrinol. Metab. 87, 5209-5219
25. Wang, L. H., and Kulmacz, R. J. (2002) Thromboxane synthase: structure and function of protein and gene. Prostaglandins Other Lipid Mediat. 68-69, 409-422
26. 2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology 124, 18-25
27. 4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J. Clin. Invest. 109, 883-893
28. 4 receptor antagonist on osteoclast formation and bone resorption in vitro. Bone 30, 159-163
29. Talley, J. J., Brown, D. L., Carter, J. S., Graneto, M. J., Koboldt, C. M., Masferrer, J. L., Perkins, W. E., Rogers, R. S., Shaffer, A. F., Zhang, Y. Y., et al. (2000) 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J. Med. Chem. 43, 775-777
30. Riendeau, D., Percival, M. D., Brideau, C., Charleson, S., Dube, D., Ethier, D., Falgueyret, J. P., Friesen, R. W., Gordon, R., Greig, G., et al. (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 296, 558-566
31. van Ryn, J., Trummlitz, G., and Pairet, M. (2000) COX-2 selectivity and inflammatory processes. Curr. Med. Chem. 7, 1145-1161
32. Cannon, G. W., Caldwell, J. R., Holt, P., McLean, B., Seidenberg, B., Bolognese, J., Ehrich, E., Mukhopadhyay, S., and Daniels, B. (2000) Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum. 43, 978-987
33. Lisse, J. R., Perlman, M., Johansson, G., Shoemaker, J. R., Schechtman, J., Skalky, C. S., Dixon, M. E., Polis, A. B., Mollen, A. J., Geba, G. P., et al. (2003) Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann. Intern. Med. 139, 539-546
34. Bensen, W. G., Fiechtner, J. J., McMillen, J. I., Zhao, W. W., Yu, S. S., Woods, E. M., Hubbard, R. C., Isakson, P. C., Verburg, K. M., and Geis, G. S. (1999) Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin. Proc. 74, 10951105.
35. Makarowski, W., Zhao, W. W., Bevirt, T., and Recker, D. P. (2002) Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 10, 290-296
36. Leung, A. T., Malmstrom, K., Gallacher, A. E., Sarembock, B., Poor, G., Beaulieu, A., Castro, R., Sanchez, M., Detora, L. M., and Ng, J. (2002) Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr. Med. Res. Opin. 18, 49-58
37. Zacher, J., and Schattenkirchner, M. (2002) Patient and physician satisfaction with rofecoxib in osteoarthritis: results of a post-marketing surveillance study in primary care in Germany. Curr. Med. Res. Opin. 18, 229-236
38. Svensson, C. I., and Yaksh, T. L. (2002) The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing. Annu. Rev. Pharmacol. Toxicol. 42, 553-583
39. 2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J. Neurosci. 21, 5847-5853
40. Ibuki, T., Matsumura, K., Yamazaki, Y., Nozaki, T., Tanaka, Y., and Kobayashi, S. (2003) Cyclooxygenase-2 is induced in the endothelial cells throughout the central nervous system during carrageenan-induced hind paw inflammation; its possible role in hyperalgesia. J. Neurochem. 86, 318-328
41. Samad, T. A., Moore, K. A., Sapirstein, A., Billet, S., Allchorne, A., Poole, S., Bonventre, J. V., and Woolf, C. J. (2001) Interleukin-1β -mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410, 471-475
42. Morrison, B. W., Christensen, S., Yuan, W., Brown, J., Amlani, S., and Seidenberg, B. (1999) Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin. Ther. 21, 943-953
43. Malmstrom, K., Fricke, J. R., Kotey, P., Kress, B., and Morrison, B. (2002) A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and -active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model. Clin. Ther. 24, 1549-1560
44. Khan, A. A., Brahim, J. S., Rowan, J. S., and Dionne, R. A. (2002) In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model. Clin. Pharmacol. Ther. 72, 44-49
45. Daniels, S. E., Desjardins, P.J., Talwalker, S., Recker, D. P., and Verburg, K. M. (2002) The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. J. Am. Dent. Assoc. 133, 611-621
46. Daniels, S. E., Talwalker, S., Torri, S., Snabes, M. C., Recker, D. P., and Verburg, K. M. (2002) Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Obstet. Gynecol. 100, 350-358
47. Malmstrom, K., Kotey, P., Cichanowitz, N., Daniels, S., and Desjardins, P. J. (2003) Analgesic efficacy of etoricoxib in primary dysmenorrhea: results of a randomized, controlled trial. Gynecol. Obstet. Invest. 56, 65-69
48. Buvanendran, A., Kroin, J. S., Tuman, K. J., Lubenow, T. R., Elmofty, D., Moric, M., and Rosenberg, A. G. (2003) Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial. J. Am. Med. Assoc. 290, 2411-2418
49. Dilger, K., Herrlinger, C., Peters, J., Seyberth, H. W., Schweer, H., and Klotz, U. (2002) Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. J. Clin. Pharmacol. 42, 985-994
50. Schwartz, J. I., Chan, C. C., Mukhopadhyay, S., McBride, K. J., Jones, T. M., Adcock, S., Moritz, C., Hedges, J., Grasing, K., Dobratz, D., et al. (1999) Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin. Pharmacol. Ther. 65, 653-660
51. Rossat, J., Maillard, M., Nussberger, J., Brunner, H. R., and Burnier, M. (1999) Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin. Pharmacol. Ther. 66, 76-84
52. Patrignani, P., Capone, M. L., and Tacconelli, S. (2003) Clinical pharmacology of etoricoxib: a novel selective COX-2 inhibitor. Expert Opin. Pharmacother. 4, 265-284
53. Alsalameh, S., Burian, M., Mahr, G., Woodcock, B. G., and Geisslinger, G. (2003) The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor. Aliment. Pharmacol. Ther. 17, 489-501
54. Whelton, A., Schulman, G., Wallemark, C., Drower, E. J., Isakson, P. C., Verburg, K. M., and Geis, G. S. (2000) Effects of celecoxib and naproxen on renal function in the elderly. Arch. Intern. Med. 160, 1465-1470
55. Swan, S. K., Rudy, D. W., Lasseter, K. C., Ryan, C. F., Buechel, K. L., Lambrecht, L. J., Pinto, M. B., Dilzer, S. C., Obrda, O., Sundblad, K. J., et al. (2000) Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann. Intern. Med. 133, 1-9
56. Whelton, A., Fort, J. G., Puma, J. A., Normandin, D., Bello, A. E., Verburg, K. M., and Study Group, S. U. C. C. E. S. S. V. I. (2001) Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am. J. Ther. 8, 85-95
57. Whelton, A., White, W. B., Bello, A. E., Puma, J. A., Fort, J. G., and Investigators, S. U. C. C. E. S. S.-V. I. I. (2002) Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am. J. Cardiol. 90, 959-963
58. Singh, G., Miller, J. D., Huse, D. M., Pettitt, D., D'Agostino, R. B., and Russell, M. W. (2003) Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. J. Rheumatol. 30, 714-719
59. 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8, 289-293
60. Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946-1952
61. Phillips, R. K., Wallace, M. H., Lynch, P. M., Hawk, E., Gordon, G. B., Saunders, B. P., Wakabayashi, N., Shen, Y., Zimmerman, S., Godio, L., et al. (2002) A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50, 857-860
62. Hallak, A., Alon-Baron, L., Shamir, R., Moshkowitz, M., Bulvik, B., Brazowski, E., Halpern, Z., and Arber, N. (2003) Rofecoxib reduces polyp recurrence in familial polyposis. Dig. Dis. Sci. 48, 1998-2002
63. Becerra, C. R., Frenkel, E. P., Ashfaq, R., and Gaynor, R. B. (2003) Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. Int. J. Cancer 105, 868-872
64. Fenwick, S. W., Toogood, G. J., Lodge, J. P., and Hull, M. A. (2003) The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology 125, 716-729
65. Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348, 891-899
66. Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., Petrelli, N., Pipas, J. M., Karp, D. D., Loprinzi, C. L., et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 348, 883-890
67. Thun, M. J., Henley, S.J., and Patrono, C. (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 94, 252-266
68. Nash, G. F., Turner, L. F., Scully, M. F., and Kakkar, A. K. (2002) Platelets and cancer. Lancet Oncol. 3, 425-430
69. 2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 10, 447-453
70. 2 levels as a biomarker. Cancer Epidemiol Biomarkers Prev. 11, 275-279
71. Wick, M., Hurteau, G., Dessev, C., Chan, D., Geraci, M. W., Winn, R. A., Heasley, L. E., and Nemenoff, R. A. (2002) Peroxisome proliferator-activated receptor-γ is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol. Pharmacol. 62, 1207-1214
72. Taylor, M. T., Lawson, K. R., Ignatenko, N. A., Marek, S. E., Stringer, D. E., Skovan, B. A., and Gerner, E. W. (2000) Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer Res. 60, 6607-6610
73. Fujita, M., Fukui, H., Kusaka, T., Morita, K., Fujii, S., Ueda, Y., Chiba, T., Sakamoto, C., Kawamata, H., and Fujimori, T. (2000) Relationship between cyclooxygenase-2 expression and K-ras gene mutation in colorectal adenomas. J. Gastroenterol. Hepatol. 15, 1277-1281
74. Araki, Y., Okamura, S., Hussain, S. P., Nagashima, M., He, P., Shiseki, M., Miura, K., and Harris, C. C. (2003) Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res. 63, 728-734
75. Boon, E. M., Keller, J.J., Wormhoudt, T. A., Giardiello, F. M., Offerhaus, G. J., Van Der Neut, R., and Pals, S. T. (2004) Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br. J. Cancer 90, 224-229
76. Saukkonen, K., Nieminen, O., van Rees, B., Vilkki, S., Harkonen, M., Juhola, M., Mecklin, J. P., Sipponen, P., and Ristimaki, A. (2001) Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin. Cancer Res. 7, 1923-1931
77. Jiang, X. H., Lam, S. K., Lin, M. C., Jiang, S. H., Kung, H. F., Slosberg, E. D., Soh, J. W., Weinstein, I. B., and Wong, B. C. (2002) Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta(1)-dependent pathway. Oncogene 21, 6113-6122
78. Buttar, N. S., Wang, K. K., Leontovich, O., Westcott, J. Y., Pacifico, R. J., Anderson, M. A., Krishnadath, K. K., Lutzke, L. S., and Burgart, L. J. (2002) Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 122, 1101-1112
79. Kaur, B. S., Khamnehei, N., Iravani, M., Namburu, S. S., Lin, O., and Triadafilopoulos, G. (2002) Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 123, 60-67
80. Tucker, O. N., Dannenberg, A. J., Yang, E. K., Zhang, F., Teng, L., Daly, J. M., Soslow, R. A., Masferrer, J. L., Woerner, B. M., Koki, A. T., et al. (1999) Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 59, 987-990
81. Schuller, H. M., Zhang, L., Weddle, D. L., Castonguay, A., Walker, K., and Miller, M. S. (2002) The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J. Cancer Res. Clin. Oncol. 128, 525-532
82. Crane, C. H., Mason, K., Janjan, N. A., and Milas, L. (2003) Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. Am. J. Clin. Oncol. 26, S81-S84
83. Bae, S. H., Jung, E. S., Park, Y. M., Kim, B. S., Kim, B. K., Kim, D. G., and Ryu, W. S. (2001) Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin. Cancer Res. 7, 1410-1418
84. Nagatsuka, I., Yamada, N., Shimizu, S., Ohira, M., Nishino, H., Seki, S., and Hirakawa, K. (2002) Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer. Int. J. Cancer 100, 515-519
85. Altorki, N. K., Keresztes, R. S., Port, J. L., Libby, D. M., Korst, R. J., Flieder, D. B., Ferrara, C. A., Yankelevitz, D. F., Subbaramaiah, K., Pasmantier, M. W., et al. (2003) Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J. Clin. Oncol. 21, 2645-2650
86. Sabino, M. A., Ghilardi, J. R., Jongen, J. L., Keyser, C. P., Luger, N. M., Mach, D. B., Peters, C. M., Rogers, S. D., Schwei, M. J., de Felipe, C., et al. (2002) Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res. 62, 7343-7349
87. Connolly, E. M., Harmey, J. H., O'Grady, T., Foley, D., Roche-Nagle, G., Kay, E., and Bouchier-Hayes, D. J. (2002) Cyclooxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. Br. J. Cancer 87, 231-237
88. Chow, L. W., Wong, J. L., and Toi, M. (2003) Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report. J. Steroid Biochem. Mol. Biol. 86, 443-447
89. Zhang, X., Morham, S. G., Langenbach, R., Baggs, R. B., and Young, D. A. (2000) Lack of cyclooxygenase-2 inhibits growth of teratocarcinomas in mice. Exp. Cell Res. 254, 232-240
90. Launer, L. (2003) Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer's disease: dissecting the epidemiological evidence. Drugs 63, 731-739
91. Fiala, M., Liu, Q. N., Sayre, J., Pop, V., Brahmandam, V., Graves, M. C., and Vinters, H. V. (2002) Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. Eur. J. Clin. Invest. 32, 360-371
92. Hoozemans, J.J., Bruckner, M. K., Rozemuller, A.J., Veerhuis, R., Eikelenboom, P., and Arendt, T. (2002) Cyclin D1 and cyclin E are co-localized with cyclo-oxygenase 2 (COX-2) in pyramidal neurons in Alzheimer disease temporal cortex. J. Neuropathol. Exp. Neurol. 61, 678-688
93. Hwang, D. Y., Chae, K. R., Kang, T. S., Hwang, J. H., Lim, C. H., Kang, H. K., Goo, J. S., Lee, M. R., Lim, H. J., Min, S. H., et al. (2002) Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer's disease. FASEB J. 16, 805-813
94. Xiang, Z., Ho, L., Valdellon, J., Borchelt, D., Kelley, K., Spielman, L., Aisen, P. S., and Pasinetti, G. M. (2002) Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol. Aging 23, 327-334
95. Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216
96. Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 112, 440-449
97. Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R.,Jin, S., Thomas, R. G., and Thal, L. J. (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. Alzheimer's Disease Cooperative Study. J. Am. Med. Assoc. 289, 2819-2826
98. Kniss, D. A. (1999) Cyclooxygenases in reproductive medicine and biology. J. Soc. Gynecol. Invest. 6, 285-292
99. Pall, M., Friden, B. E., and Brannstrom, M. (2001) Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study. Hum. Reprod. 16, 1323-1328
100. Lazarus, M., Munday, C.J., Eguchi, N., Matsumoto, S., Killian, G. J., Kubata, B. K., and Urade, Y. (2002) Immunohistochemical localization of microsomal PGE synthase-1 and cyclooxygenases in male mouse reproductive organs. Endocrinology 143, 2410-2419
101. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343, 1520-1528
102. Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., et al. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J. Am. Med. Assoc. 284, 1247-1255
103. Juni, P., Rutjes, A. W., and Dieppe, P. A. (2002) Are selective COX 2 inhibitors superior to traditional non steroidal antiinflammatory drugs? BMJ 324, 1287-1288
104. Chan, F. K., Hung, L. C., and Suen, B. Y. (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N. Engl. J. Med. 347, 2104-2110
105. Sikes, D. H., Agrawal, N. M., Zhao, W. W., Kent, J. D., Recker, D. P., and Verburg, K. M. (2002) Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur. J. Gastroenterol. Hepatol. 14, 1101-1111
106. Goldstein, J. L., Kivitz, A. J., Verburg, K. M., Recker, D. P., Palmer, R. C., and Kent, J. D. (2003) A comparison of the upper gastrointestinal mucosal effects of valclecoxib, naproxen and placebo in healthy elderly subjects. Aliment. Pharmacol. Ther. 18, 125-132
107. Hunt, R. H., Harper, S., Watson, D. J., Yu, C., Quan, H., Lee, M., Evans, J. K., and Oxenius, B. (2003) The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am. J. Gastroenterol. 98, 1725-1733
108. Hunt, R. H., Harper, S., Callegari, P., Yu, C., Quan, H., Evans, J., James, C., Bowen, B., and Rashid, F. (2003) Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment. Pharmacol. Ther. 17, 201-210
109. Rordorf, C., Kellett, N., Mair, S., Ford, M., Milosavljev, S., Branson, J., and Scott, G. (2003) Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects. Aliment. Pharmacol. Ther. 18, 533-541
110. Zimmermann, K. C., Sarbia, M., Schror, K., and Weber, A. A. (1998) Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol. Pharmacol. 54, 536-540
111. McCartney, S. A., Mitchell, J. A., Fairclough, P. D., Farthing, M. J. G., and Warner, T. D. (1999) Selective COX-2 inhibitors and human inflammatory bowel disease. Aliment. Pharmacol. Ther. 13, 1115-1117
112. Wight, N.J., Gottesdiener, K., Garlick, N. M., Atherton, C. T., Novak, S., Gertz, B.J., Calder, N. A., Cote,J., Wong, P., Dallob, A., et al. (2001) Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. Gastroenterology 120, 867-873
113. Wallace, J. L., McKnight, W., Reuter, B. K., and Vergnolle, N. (2000) NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119, 706-714
114. Gretzer, B., Maricic, N., Respondek, M., Schuligoi, R., and Peskar, B. M. (2001) Effects of specific inhibition of cyclooxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br. J. Pharmacol. 132, 1565-1573
115. Baatar, D., Jones, M. K., Pai, R., Kawanaka, H., Szabo, I. L., Moon, W. S., Kitano, S., and Tarnawski, A. S. (2002) Selective cyclooxygenase-2 blocker delays healing of esophageal ulcers in rats and inhibits ulceration-triggered c-Met/hepatocyte growth factor receptor induction and extracellular signal-regulated kinase 2 activation. Am. J. Pathol. 160, 963-972
116. Konstam, M. A., Weir, M. R., Reicin, A., Shapiro, D., Sperling, R. S., Barr, E., and Gertz, B. J. (2001) Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 104, 2280-2288
117. Reicin, A. S., Shapiro, D., Sperling, R. S., Barr, E., and Yu, Q. (2002) Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am. J. Cardiol. 89, 204-209
118. Mukherjee, D., Nissen, S. E., and Topol, E. J. (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. J. Am. Med. Assoc. 286, 954-959
119. Chiolero, A., Maillard, M. P., and Burnier, M. (2002) Cardiovascular hazard of selective COX-2 inhibitors: myth or reality? Exp. Opin. Drug Safety 1, 45-52
120. White, W. B., Faich, G., Whelton, A., Maurath, C., Ridge, N.J., Verburg, K. M., Geis, G. S., and Lefkowith, J. B. (2002) Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am. J. Cardiol. 89, 425-430
121. Ray, W. A., Stein, C. M., Daugherty, J. R., Hall, K., Arbogast, P. G., and Griffin, M. R. (2002) COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360, 1071-1073
122. Mamdani, M., Rochon, P., Juurlink, D. N., Anderson, G. M., Kopp, A., Naglie, G., Austin, P. C., and Laupacis, A. (2003) Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch. Intern. Med. 163, 481-486
123. Rahme, E., Pilote, L., and LeLorier, J. (2002) Association between naproxen use and protection against acute myocardial infarction. Arch. Intern. Med. 162, 1111-1115
124. Solomon, D. H., Glynn, R. J., Levin, R., and Avorn, J. (2002) Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch. Intern. Med. 162, 1099-1104
125. Chenevard, R., Hurlimann, D., Bechir, M., Enseleit, F., Spieker, L., Hermann, M., Riesen, W., Gay, S., Gay, R. E., Neidhart, M., et al. (2003) Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107, 405-409
126. Altman, R., Luciardi, H. L., Muntaner, J., Del Rio, F., Berman, S. G., Lopez, R., and Gonzalez, C. (2002) Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Non-steroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) Pilot Study. Circulation 106, 191-195
127. Leese, P. T., Hubbard, R. C., Karim, A., Isakson, P. C., Yu, S. S., and Geis, G. S. (2000) Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J. Clin. Pharmacol. 40, 124-132
128. McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., and FitzGerald, G. A. (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA 96, 272-277
129. Rinder, H. M., Tracey, J. B., Souhrada, M., Wang, C., Gagnier, R. P., and Wood, C. C. (2002) Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebo-controlled trial. J. Clin. Pharmacol. 42, 881-886
130. Layton, D., Hughes, K., Harris, S., and Shakir, S. A. (2003) Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatol. 42, 1354-1364
131. Layton, D., Heeley, E., Hughes, K., and Shakir, S. A. (2003) Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatol. 42, 1342-1353
132. Ouellet, M., Riendeau, D., and Percival, M. D. (2001) A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc. Natl. Acad. Sci. USA 98, 4583-4588
133. MacDonald, T. M., and Wei, L. (2003) Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361, 573-574
134. Greenberg, H. E., Gottesdiener, K., Huntington, M., Wong, P., Larson, P., Wildonger, L., Gillen, L., Dorval, E., and Waldman, S. A. (2000) A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J. Clin. Pharmacol. 40, 1509-1515
135. Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., and FitzGerald, G. A. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. EngI. J. Med. 345, 1809-1817
136. Wilner, K. D., Rushing, M., Walden, C., Adler, R., Eskra, J., Noveck, R., and Vargas, R. (2002) Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J. Clin. Pharmacol. 42, 1027-1030
137. Solomon, D. H., Karlson, E. W., Rimm, E. B., Cannuscio, C. C., Mandl, L. A., Manson, J. E., Stampfer, M. J., and Curhan, G. C. (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107, 1303-1307
138. Watson, D. J., Rhodes, T., Cai, B., and Guess, H. A. (2002) Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch. Intern. Med. 162, 1105-1110
139. Curhan, G. C., Willett, W. C., Rosner, B., and Stampfer, M. J. (2002) Frequency of analgesic use and risk of hypertension in younger women. Arch. Intern. Med. 162, 2204-2208
140. Widlansky, M. E., Price, D. T., Gokce, N., Eberhardt, R. T., Duffy, S. J., Holbrook, M., Maxwell, C., Palmisano, J., Keaney, J. F., Jr., Morrow, J. D., et al. (2003) Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 42, 310-315
141. Stevenson, D. D., and Simon, R. A. (2001) Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J. Allergy Clin. Immunol. 108, 47-51
142. Woessner, K. M., Simon, R. A., and Stevenson, D. D. (2002) The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum. 46, 2201-2206
143. Szczeklik, A., Nizankowska, E., Bochenek, G., Nagraba, K., Mejza, F., and Swierczynska, M. (2001) Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin. Exp. Allergy 31, 219-225
144. Martin-Garcia, C., Hinojosa, M., Berges, P., Camacho, E., Garcia-Rodriguez, R., and Alfaya, T. (2003) Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. J. Investig. Allergol. Clin. Immunol. 13, 20-25
145. Bavbek, S., Celik, G., Ediger, D., Mungan, D., Demirel, Y. S., and Misirligil, Z. (1999) The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance. J. Asthma 36, 657-663
146. Quiralte, J., Saenz de San Pedro, B., and Florido, J. J. (2002) Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann. Allergy Asthma Immunol. 89, 63-66
147. Elder, C. L., Dahners, L. E., and Weinhold, P. S. (2001) A cyclooxygenase-2 inhibitor impairs ligament healing in the rat. Am. J. Sports Med. 29, 801-805
148. Simon, A. M., Manigrasso, M. B., and O'Connor, J. P. (2002) Cyclo-oxygenase 2 function is essential for bone fracture healing. J. Bone Miner. Res. 17, 963-976
149. Kitahara, M., Eitner, F., Ostendorf, T., Kunter, U., Janssen, U., Westenfeld, R., Matsui, K., Keljaschki, D., and Floege, J. (2002) Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis. J. Am. Soc. Nephrol. 13, 1261-1270
150. Long, J., Lewis, S., Kuklo, T., Zhu, Y., and Riew, K. D. (2002) The effect of cyclooxygenase-2 inhibitors on spinal fusion. J. Bone Joint Surg. Am. 84-A, 1763-1768
151. Brown, K. M., Saunders, M. M., Kirsch, T., Donahue, H. J., and Reid, J. S. (2004) Effect of COX-2-specific inhibition on fracture-healing in the rat femur. J. Bone Joint Surg. Am. 86, 116-123
152. Goodman, S., Ma, T., Trindade, M., Ikenoue, T., Matsuura, I., Wong, N., Fox, N., Genovese, M., Regula, D., and Smith, R. L. (2002) COX-2 selective NSAID decreases bone ingrowth in vivo. J. Orthop. Res. 20, 1164-1169
153. Einhorn, T. A. (1999) Point of view (Comment on Spine 1999; 24 (21): 2188-2194). Spine 24, 2193-2194
154. Einhorn, T. A. (1999) Point of view (Comment on Spine 1999; 24 (21): 2188-2194). Spine 24, 2193-2194
155. Laulederkind, S.J., Thompson-Jaeger, S., Goorha, S., Chen, Q., Fu, A., Rho, J. Y., Ballou, L. R., and Raghow, R. (2002) Both constitutive and inducible prostaglandin H synthase affect dermal wound healing in mice. Lab. Invest. 82, 919-927
156. Blomme, E. A., Chinn, K. S., Hardy, M. M., Casler, J. J., Kim, S. H., Opsahl, A. C., Hall, W. A., Trajkovic, D., Khan, K. N., and Tripp, C. S. (2003) Selective cyclooxygenase-2 inhibition does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice. Br. J. Dermatol. 148, 211-223
157. Wilgus, T. A., Vodovotz, Y., Vittadini, E., Clubbs, E. A., and Oberyszyn, T. M. (2003) Reduction of scar formation in full-thickness wounds with topical celecoxib treatment. Wound Repair Regen. 11, 25-34
158. Gilroy, D. W., Colville-Nash, P. R., Willis, D., Chivers, J., Paul-Clark, M. J., and Willoughby, D. A. (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5, 698-701
159. Warner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., and Vane, J. R. (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. USA 96, 7563-7568